



# Quantitative Analysis of monoclonal antibodies at the low ng/mL range from serum samples via affinity enrichment coupled LC-MS/MS

---

*Dr. Stephanie Fischmann,*

*Department of Protein-Bioanalysis,*

*Abbott GmbH & Co. KG, Ludwigshafen*

# How to quantitate a monoclonal Antibody ?

---

Technologies used up to now



**LIGAND BINDING ASSAYS**



- ELISA (Biotin - POD)
- ECL

- HTRF (under evaluation)
- Luminex (under evaluation)

# Ligand binding assays (LBA)

Based on high affinity protein-protein or similar inter-molecule interactions  
Standard assay for Pharmacokinetic (PK) and Anti-Drug-Antibody (ADA) analysis

- Non-linearity of response/ Dilution linearity
- Matrix effects
- (Assay range)



# How to quantitate a monoclonal Antibody ?

---

Technologies used up to now

LIGAND BINDING ASSAYS


- ELISA (Biotin - POD)
- ECL

- HTRF (under evaluation)
- Luminex (under evaluation)


- Mass-spectrometry?

# Theoretical approaches

- Bottom-up (Measurement of tryptic peptides of the Antibody)



- Top-down (Measurement of intact Antibody)



# Peptides of antibodies

## Heavy Chain

AGISKRQRST AGISKRQRST AGISKRQRST AGISKRQRST AGISKRQRST  
AGISKRQRST AGISKRQRST AGISKRQRST AGISKRQRST AGISKRQRST  
AGISKRQRST AGISKRQRST AGISKRQRST AGISKRQRST AGISKRQRST  
AGISKRQRST AGISKRQRST AGISKRQRST AGISKRQRST AGISKRQRST  
AGISKRQRST AGISKRQRST AGISKRQRST AGISKRQRST AGISKRQRST  
AGISKRQRST AGISKRQRST AGISKRQRST AGISKRQRST AGISKRQRST  
AGISKRQRST AGISKRQRST AGISKRQRST AGISKRQRST AGISKRQRST  
AGISKRQRST AGISKRQRST AGISKRQRST AGISKRQRST AGISKRQRST  
TSRQ

## Light Chain

AGISKRQRST AGISKRQRST AGISKRQRST AGISKRQRST AGISKRQRST  
AGISKRQRST AGISKRQRST AGISKRQRST AGISKRQRST AGISKRQRST  
AGISKRQRST AGISKRQRST AGISKRQRST AGISKRQRST AGISKRQRST  
AGISKRQRST AGISKRQRST AGISKRQRST AGISKRQRST AGISKRQRST  
AGISKRQRST AGISKRQRST AGISKRQRST AGISKRQRST AGISKRQRST  
AGISKRQRST AGISKRQRST AGISKRQRST AGISKRQRST AGISKRQRST  
ISKQASTRA TVE

aa-sequence is only a fake

Variable Domain  
Linkers  
Constant Region

CDR

# Strategy for Selecting Peptides for Quantitation

Theoretical # of peptides: 25-30 from LC, 45-50 from HC

ID “unique” peptides from CDR and linker regions

Filter unique peptides based on composition, ideally

- MW ~1500 Da
- No oxidizable residues (C, M, W)
- No unstable sequences (DG, N-term Q, KK, RR)
- Proline is desirable

Search databases to ID duplicate sequences


- Are the peptides species-specific?
- Will sample prep remove duplicate peptides?

Protein Digestion

- Confirm that expected peptides are produced
- Incomplete cleavage minimized

MS evaluation

- Select peptides that ionize and fragment appropriately



# Database Searching – are the Peptides Unique?



Used to ID prototypic peptides that do not match other known amino acid sequences

- 18 databases composed of 37,982,376 protein sequences from 7 species
- 12 databases composed of 191,433,748 nucleotide sequences translated into protein (6 frames)

## Peptide-Protein Alignment Summary

	Peptide Sequence	# aa	Chain	# hits	Align % identity	Considerations
1	AGISWRQRST AGISKRQRST AGISKRWRSR	24	H	393	100-80	Oxidation: 2 W
2		14	H	1968	92.86-81.25	
3		24	H	423	88.0-76.92	Oxidation: M; Pyro-glu formation; undercuts
4		22	H	1888	90.91-69.23	Contains DG
5		16	L	2032	100-93.75	100% identical to IgG Kappas
6		26	L	2040	96.15-84.62	Oxidation: C

aa-sequence is only a fake

Provided by Advanced Tech group



# Candidate Peptides (from CDR/ Linker region)


## What is left after candidate selection?

Sequence	Residues	CDR or Linker	Unique Seq.	Heavy (H)/ Light (L) Chain	MW (Da)
AGISKRQRST AGISKRQRST AGISKRQRST	71-80	CDR	Yes	HC	2662.85
AGISKRQRST AGI	135-149	Linker	Yes	HC	1440.62
KRQRST AGISKRQRST AG	113-165	CDR	Yes	HC	2933.16
ISKRQRST AGISKRQRST AGISKRQRST A	238-257	CDR	Yes	HC	2219.35
AGISKRQRST AGISKRQRST AGISKR	61-96	CDR	Yes	LC	1675.95
KRQRST AGISKRQRST AGISKRQRST AGIS	209-225	CDR	Yes	LC	2853.16


aa-sequence is only a fake

# MS Approach for Absolute Antibody Quantitation

## Antibody digestion



## Analysis of peptides by LC-MS and quantitation



# Production of Labeled Antibody

A stable CHO cell line expressing monoclonal antibody is adapted to and cultured in the following medium:

- DMEM-F/12 Flex medium (Invitrogen) supplemented with glucose, L-glutamine, dialyzed low IgG FBS, penicillin G, streptomycin sulfate, and methothrexate

Cells grown in 2L roller bottles

Cells were transferred in



- SILAC Advanced DMEM-F/12 Flex medium (Invitrogen) supplemented as above. This medium lacks the amino acids lysine and arginine, and was supplemented with [U-<sup>13</sup>C<sub>6</sub>]-L-lysine and [U-<sup>13</sup>C<sub>6</sub>, <sup>15</sup>N<sub>4</sub>]-L-arginine

Cells cultured for 15 days in the labeled medium; supernatant harvested

MS showed uniform incorporation of labeled amino acids in greater than 98% of the sample



★ - Isotope labeled Lys or Arg



Provided by Advanced Tech group


# Method development: Ion chromatogram of Tryptic Digest

## Digestion protocol:

- 2,5 µL monoclonal antibody
- + 2 µL DTT
- + 10 µL Iodoacetic acid
  
- + 0.1 M Tris , pH 8
- + Trypsin (Promega)
- => overnight, 37 ° C
- + 5 N HCl

## LC/MS protocol:

- Thermo Accela U-HPLC
  - BEH300 C18 150mm\*2.1mm\*1.7µm
  - Thermo Orbitrap LTQ XL
- Flow: 250µL/min
- Linear gradient profile
- Full Scan 500-3000 (LTQ)



## Calculated sequence coverage:

**LC: 95%**

**HC: 92%**


Missing regions result from:

- Peptides too small to detect or too large to fragment
- Glycosylated peptides



# Method Improvement: Additional SPE Purification Step

Additional solid phase extraction

led to improved background signal




# Evaluate affinity enrichment



# Peptide Recovery after affinity enrichment

## SDS-PAGE/ Coomassie and Typtic Digest




# Improvements for high throughput

---

- Affinity chromatography is done in 96-well plate format
- Tryptic digest is done in 96-well plate format
- Tryptic digest in 60 min
- Separation via SPE (automated, ready to inject)
- Chromatographic run 5 min




# Method scheme



# Peptides on focus for quantitation

## Transitions for the three peptides on focus



- 858: 857.94 → 1130.91
- 868: 867.96 → 951.36
- 994: 994.11 → 893.00





# Quantitation via Tryptic Peptides – Quantitation is achievable at low ng/mL Levels

- Antibody was purified from serum using Anti-idiotypic Ab coupled to sepharose
- After tryptic digestion, samples were analyzed using MS/MS (Orbitrap LTQ XL)
- The main fragment ion of each peptide was used for quantitation

Peptide 858





Peptide 868



# Quantitation via Tryptic Peptides – Quantitation is achievable down to lower ng/mL Levels

## For peptide 994





Lowest level: 0.365 µg/mL



Highest level: 365 µg/mL

# Quantitation over a broad dynamic range: up to 15,000 µg/mL as highest level

## Peptide 858





## Peptide 868



# Outlook for excellent sensitivity

Correlation coefficient:  $r = 0.999111$ ,  $r^2 = 0.998223$   
Calibration curve:  $336.55 * x + -11.2272$   
Response type: External Std, Area  
Curve type: Linear, Origin: Exclude, Weighting: 1/x, Axis trans: None



**Purity of internal standard 98 %**



**Only external calibration**



**Expected LLOQ  
0.1 ng/mL**

# Cross-validation to Ligand Binding Assay

---

- **design:**


- 57 serum samples from three dosing groups were analyzed
- 6 full PK profiles (male/female)

- **outcome:**


- 91% samples passed ISR acceptance for MS-Methods
- 98% samples passed ISR acceptance for LBA

# Results of cross-validation


time/conc. profile for 20 mg/kg dose



time/conc. profile for 60 mg/kg dose



time/conc. profile for 200 mg/kg






# Statistical analysis of cross-validation results

$$\frac{(\text{ISR value} - \text{original value})}{\text{mean}} * 100\%$$

Residuals




2% outside < 30%



9% outside < 20%

# Challenges of LBA vs. reasons for MS method

Ligand Binding Assays	MS of Proteins
well established for Proteins (discovery, clinic, CRO)	Established in Protein world for <b>relative small</b> molecules only
tool kits commercially available	Tool kits commercially available
high specificity - epitope	<b>High specificity (unique peptide)</b>
highly sensitive (ng/mL)	<b>Sensitivity ~1-5 ng/mL</b> <b>10 fold more sensitive than LBA</b>
measures free Ab (total Ab)	<b>measures total Ab only</b> <b>different picture w affinity step</b>
relative cheap consumables (ECL plates)	Relative cheap consumables (Trypsin)
Parallel measurement on MT-plates	Sequential measurement, but full automation established
<b>Indirect assay principle</b>	<b>Direct assay principle</b>
relies on high affinity detection Abs	relies on mass/charge separation
<b>Produces nonlinear Calibration Curves = robustness, small dynamic range</b>	Produces linear calibration curves, wide dynamic range
<b>Assay interference = dilution nonlinearity,</b>	no interference after cleanup procedure
<b>Careful optimization and validation of assays = time critical</b>	Fast optimization and validation



potentially 0.1 ng/mL



# Thank you team

---

Volker Berweck and Kathrina Jäger, Dietmar Seemann, Gregor Schaffar  
*Protein Bioanalysis-Ludwigshafen*

Laura J. Miesbauer, Melanie J. Patterson, Steven P. Cepa, and Robert  
W. Johnson  
*Structural Chemistry, Advanced Technology, Chicago*

Marc R. Lake, Jeanne Cabel and Karl Walter  
*Protein Biochemistry, Advanced Technology, Chicago*

Paul L. Richardson  
*Molecular Probes, Advanced Technology, Chicago*

Randy Metzger  
*Discovery IT-Informatics, Advanced Technology, Chicago*